Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
- PMID: 12618528
- PMCID: PMC151902
- DOI: 10.1172/JCI17223
Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
Abstract
To elucidate the function of PPARgamma in leptin-deficient mouse (ob/ob) liver, a PPARgamma liver-null mouse on an ob/ob background, ob/ob-PPARgamma(fl/fl)AlbCre(+), was produced using a floxed PPARgamma allele, PPARgamma(fl/fl), and Cre recombinase under control of the albumin promoter (AlbCre). The liver of ob/ob-PPARgamma(fl/fl)AlbCre(+) mice had a deletion of exon 2 and a corresponding loss of full-length PPARgamma mRNA and protein. The PPARgamma-deficient liver in ob/ob mice was smaller and had a dramatically decreased triglyceride (TG) content compared with equivalent mice lacking the AlbCre transgene (ob/ob-PPARgamma(fl/fl)AlbCre(-)). Messenger RNA levels of the hepatic lipogenic genes, fatty acid synthase, acetyl-CoA carboxylase, and stearoyl-CoA desaturase-1, were reduced in ob/ob-PPARgamma(fl/fl)AlbCre(+) mice, and the levels of serum TG and FFA in ob/ob-PPARgamma(fl/fl)AlbCre(+) mice were significantly higher than in the control ob/ob-PPARgamma(fl/fl)AlbCre(-) mice. Rosiglitazone treatment exacerbated the fatty liver in ob/ob-PPARgamma(fl/fl)AlbCre(-) mice compared with livers from nonobese Cre(-) mice; there was no effect of rosiglitazone in ob/ob-PPARgamma(fl/fl)AlbCre(+) mice. The deficiency of hepatic PPARgamma further aggravated the severity of diabetes in ob/ob mice due to decreased insulin sensitivity in muscle and fat. These data indicate that hepatic PPARgamma plays a critical role in the regulation of TG content and in the homeostasis of blood glucose and insulin resistance in steatotic diabetic mice.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/151902/bin/JCI0317223.f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/151902/bin/JCI0317223.f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/151902/bin/JCI0317223.f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/151902/bin/JCI0317223.f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/151902/bin/JCI0317223.f5.gif)
Similar articles
-
Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012. Epub 2013 Aug 5. Metabolism. 2013. PMID: 23928105
-
Role of ChREBP in hepatic steatosis and insulin resistance.FEBS Lett. 2008 Jan 9;582(1):68-73. doi: 10.1016/j.febslet.2007.07.084. Epub 2007 Aug 14. FEBS Lett. 2008. PMID: 17716660 Review.
-
Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.Diabetes. 2006 Aug;55(8):2159-70. doi: 10.2337/db06-0200. Diabetes. 2006. PMID: 16873678
-
Hepatic CCAAT/enhancer binding protein alpha mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice.Mol Endocrinol. 2004 Nov;18(11):2751-64. doi: 10.1210/me.2004-0213. Epub 2004 Aug 19. Mol Endocrinol. 2004. PMID: 15319454
-
Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.Am J Gastroenterol. 2003 Sep;98(9):2093-7. doi: 10.1111/j.1572-0241.2003.07670.x. Am J Gastroenterol. 2003. PMID: 14499793 Review.
Cited by
-
Single-cell multiomics guided mechanistic understanding of Fontan-associated liver disease.Sci Transl Med. 2024 Apr 24;16(744):eadk6213. doi: 10.1126/scitranslmed.adk6213. Epub 2024 Apr 24. Sci Transl Med. 2024. PMID: 38657025 Free PMC article.
-
Targeting nuclear receptors for NASH/MASH: From bench to bedside.Liver Res. 2024 Mar;8(1):34-45. doi: 10.1016/j.livres.2024.03.002. Liver Res. 2024. PMID: 38544909 Free PMC article.
-
FoxO6-mediated ApoC3 upregulation promotes hepatic steatosis and hyperlipidemia in aged rats fed a high-fat diet.Aging (Albany NY). 2024 Mar 3;16(5):4095-4115. doi: 10.18632/aging.205610. Epub 2024 Mar 3. Aging (Albany NY). 2024. PMID: 38441531 Free PMC article.
-
A medium-chain fatty acid analogue prevents hepatosteatosis and decreases inflammatory lipid metabolites in a murine model of parenteral nutrition-induced hepatosteatosis.PLoS One. 2023 Dec 1;18(12):e0295244. doi: 10.1371/journal.pone.0295244. eCollection 2023. PLoS One. 2023. PMID: 38039287 Free PMC article.
-
Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice.Heliyon. 2023 Nov 4;9(11):e22051. doi: 10.1016/j.heliyon.2023.e22051. eCollection 2023 Nov. Heliyon. 2023. PMID: 38027691 Free PMC article.
References
-
- Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives. Cell. Mol. Life Sci. 2002;59:790–798. - PubMed
-
- Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann. N. Y. Acad. Sci. 2002;967:7–18. - PubMed
-
- Chawla A, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 2001;7:161–171. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous